Drug intelligence / Profile preview

doxorubicin + interferon alfa-2a

Development stage: Unknown
Lead developer: Wake Forest School of Medicine
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous, Intramuscular

Overview

A combination therapy consisting of doxorubicin, a cytotoxic anthracycline antibiotic, and interferon alfa-2a, a type I interferon with immunomodulatory properties. This combination has been studied for its potential synergistic antitumor effects, particularly in cervical cancer, hepatocellular carcinoma, and other solid tumors. The mechanism involves doxorubicin's DNA intercalation and generation of reactive oxygen species combined with interferon's immunomodulatory and antiproliferative effects.

Other names: doxorubicin + interferon alpha-2adoxorubicin + interferon alfa-2adoxorubicin + alpha-interferondoxorubicin + a2-interferonadriamycin + interferon alfa-2a

Targets

TOP2A (DNA topoisomerase II)IFNAR (Immune system modulation via type I interferon receptor)DNA

Beyond the preview

Go deeper on doxorubicin + interferon alfa-2a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on doxorubicin + interferon alfa-2a.

Explore the full profile